”We are impressed by Ascilion’s technology platform and by the team behind the company. Ascilion’s products are at the forefront and can contribute to developing and improving today’s diagnostic methods. Nordstjernan’s ambition is to continue growing in the health sector, and medical technology and diagnostics are areas we actively want to invest in. We look forward to supporting Ascilion in the company’s future development,” says Nordstjernan’s CEO Peter Hofvenstam.
The International Microneedle Conference is a global conference comprised of both industrial and academic attendees, and this event has grown steadily since its inception in 2010.
Ascilion is proud to announce its support to the conference by being a Gold Sponsor.
Come and meet part of the Ascilion team at the MICRONEEDLES conference, Hyatt At Olive 8, 1635 8th Ave, Seattle, USA between May 15 – May 17, 2023
Presentations and live demonstration of interstitial fluid sampling was held by Ascilion during the 5th Consortium Meeting in the European Project DIGIPREDICT was held at EPFL, Lausanne Switzerland.
Representatives from Charité – Universitätsmedizin Berlin and Fraunhofer Institute for Translational Medicine and Pharmacology will present “Application of hollow microneedles for skin ISF harvesting in models of allergy and chronic urticaria”at the 9th International Microdialysis Symposium, 7-9 September, 2022, Berlin, Germany
Nordstjernan is investing in Ascilion, a Swedish medtech company founded in 2012 and based in Stockholm, Sweden. Ascilion has developed and patented a technology that uses an array of hollow microneedles to extract the interstitial fluid (ISF) that surrounds the body’s cells and that is a good carrier of biomarkers. Ascilion’s technology has numerous fields of application, including within several branches of medical diagnostics. Nordstjernan will become the second largest owner in Ascilion and, as a partner to the company’s founder and current owners, the aim is to accelerate the company’s commercial development.
“We are impressed by Ascilion’s technology platform and by the team behind the company. Ascilion’s products are at the leading edge and can help develop and improve current diagnostic methods. Nordstjernan’s ambition is to continue growing in the health sector, and medtech and diagnostics are fields in which we want to actively invest. We look forward to supporting Ascilion in the company’s future development,”
says Nordstjernan’s CEO Peter Hofvenstam.
DIGIPREDICT is a pan-European research program bringing together scientific and technical excellence in multiple disciplines including informatics (machine learning), engineering (embedded systems, sensors, and wearables), medical science (organ-on-chip systems, digital medicine), translational science (clinical studies and research), ethical and regulatory frameworks. The consortium consists of three members from academia (EPFL, UTWENTE & ETHZ), two large R&D institutes (IMEC-BE & IMEC-NL), two hospitals (Charité & UBERN), two high-tech SMEs (Ascilion and EPOS) and a management and communication SME (SCIPROM) from five European countries.
Ascilion´s role in the project will be to design and manufacture chips with arrays of ultra-sharp, hollow microneedles in monocrystalline silicon using micro-electro-mechanical system (MEMS) technology.
The DIGIPREDICT, funded by the European Union's Horizon 2020 research and innovation programme, started on 1 January 2021 and will run until 31 December 2024
Presentations: “Interstitial Fluid Extracted using Hollow Microneedles - Comparison of Lipid Content in ISF vs Whole Blood”, “Sub-pressure Assisted Application of Sharp Hollow Microneedles Improves Penetration”.
Presentation: “Rapid Extraction of Interstitial Fluid using Sharp Hollow Silicon Microneedles”
Presentation: “High-yield and High-volume Fabrication of Silicon Microneedles Intended for Interstitial Fluid Extraction”
Presentation: “Extraction of Interstitial Fluid and Sensing of Glucose Levels using Microneedles and Millimetre Wave Spectroscopy”
